Skip to content

Lipella Pharmaceuticals Inc.

LIPO

CIK 0001347242

← back to feed
Revenue (TTM)
$432.93K
+19.3% YoY Q3 Nov 2025
Net Income (TTM)
−$5.33M
−8.6% YoY Q3 Nov 2025
EPS Diluted (TTM)
−$2.52
+22.2% YoY Q3 Nov 2025
Gross Margin
—
Q3 Nov 2025
Operating Margin
-1,251.5%
Q3 Nov 2025
Net Margin
-1,231.8%
Q3 Nov 2025
Free Cash Flow (TTM)
−$4.61M
Q3 Nov 2025
Cash
$1.86M
Q3 Nov 2025
Total Debt
—
Q3 Nov 2025
Shares Outstanding
4.62M sh
Q3 Nov 2025

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings